March 22, 2021
March 22, 2021 –
The U.S. FDA has approved Zegalogue® (dasiglucagon), manufactured by Zealand
Pharmaceuticals, to treat severe hypoglycemia (low blood sugar) in patients who
March 22, 2021
March 22, 2021 –
The U.S. FDA has approved an expanded indication for Exparel® (bupivacaine liposome), manufactured by Pacira Pharmaceuticals, to include use in patients
March 19, 2021
March 19, 2021 –
The U.S. FDA has approved PonvoryTM (ponesimod), manufactured by Janssen, to treat
relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated
March 18, 2021
March 18, 2021 –
The U.S. FDA has authorized revisions to fact sheets for healthcare providers on using
the following monoclonal antibody (mAb) therapies to treat COVID-19 caused by the
March 18, 2021
March 18, 2021 –
The U.S. FDA has approved a new indication for Arcalyst® (rilonacept), manufactured by Kiniksa Pharmaceuticals, to treat recurrent pericarditis (RP) and reduce the risk
March 15, 2021
March 15, 2021 –
The U.S. FDA has approved an expanded indication for Fabrazyme® (agalsidase beta),
manufactured by Genzyme, to treat patients who are at least two years old and
March 15, 2021
March 15, 2021 –
The U.S. FDA has approved KimyrsaTM (oritavancin), manufactured by Melinta
Therapeutics, to treat adults who have acute bacterial skin and skin structure infection
March 11, 2021
March 11, 2021 –
Sagent Pharmaceuticals has voluntarily recalled three lots of Phenylephrine
Hydrochloride (HCl) Injection, USP (10mg/mL), which was manufactured by